A pharmacokinetic study of Genasense [oblimersen] (Bcl-2 antisense oligonucleotide) in combination with dacarbazine (DTIC) in subjects with advanced melanoma and normal or impaired hepatic function.

Trial Profile

A pharmacokinetic study of Genasense [oblimersen] (Bcl-2 antisense oligonucleotide) in combination with dacarbazine (DTIC) in subjects with advanced melanoma and normal or impaired hepatic function.

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 04 Nov 2011

At a glance

  • Drugs Dacarbazine; Oblimersen
  • Indications Malignant melanoma
  • Focus Pharmacokinetics
  • Sponsors Genta (CEASED)
  • Most Recent Events

    • 04 Nov 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 24 Oct 2007 New trial record.
    • 23 Sep 2007 Results reported at ECCO 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top